Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (NASDAQ: DRIO) reported second quarter 2026 revenue of $5.2 million, down from $5.4 million a year ago and $5.6 million in Q1 2026, mainly due to discontinuing certain pharmaceutical-related business as it shifts toward a B2B2C annual recurring revenue model.
Gross profit rose to $3.2 million and gross margin improved to about 62% versus 55% a year earlier, with non-GAAP B2B2C gross margin near 80% for the 10th straight quarter. Operating expenses fell 21% year-over-year to $9.7 million, improving operating loss to $6.5 million and net loss to $7.9 million. The company cited $13.1 million of contracted and late-stage ARR, more than 80% multi-condition, and highlighted new commercial wins including a top‑5 national health plan expansion, a fifth Fortune 50 client, and broader reach through Solera and Amwell channel partners.
Pro forma cash, cash equivalents and short‑term deposits totaled $36.8 million after raising $22.8 million net in a July 2026 at‑the‑market registered direct offering.
DarioHealth (NASDAQ: DRIO) announced the launch of two new provider-backed programs, Dario Women™ and Dario Sleep™, expanding its AI-enabled cardiometabolic platform into women's health and sleep. The programs integrate AI-powered engagement, human behavioral coaching and licensed healthcare providers to address perimenopause/menopause-related cardiometabolic risks and obstructive sleep apnea (OSA).
According to DarioHealth, both solutions are expected to roll out to Fortune 500 and other clients in Fall 2026, with recurring digital platform revenue per engaged member per month anticipated to begin in Q4 2026 and provider-backed care revenue expected from late 2026 into early 2027. The company aims to increase revenue opportunities with existing enterprise customers by offering additional high-cost clinical categories on the same integrated platform, which already covers diabetes, hypertension, weight management, musculoskeletal, behavioral health, women's health and sleep.
DarioHealth (Nasdaq: DRIO) announced it will release financial results for the second quarter ended June 30, 2026, on Tuesday, August 11, 2026, before the market opens. Management will host a conference call and webcast at 8:30 a.m. Eastern Time the same day.
The call will feature CEO Erez Raphael, COO Lara Dodo, and CFO Chen Franco-Yehuda. Investors can join via domestic dial-in 1-800-717-1738, international dial-in 1-646-307-1865, or the Call me™ and webcast links provided. A replay will be available through August 25, 2026.
DarioHealth (NASDAQ: DRIO) announced the launch of its Integrated GLP-1 Program, the first commercial product from its collaboration with Beluga Health. The offering combines Dario’s AI-powered chronic care platform with Beluga’s network of licensed providers to deliver evaluation, prescribing of FDA-approved GLP-1 medications when clinically appropriate, and ongoing clinical oversight in a single, end-to-end experience.
The program targets a shifting reimbursement environment where employers and health plans are moving from broad GLP-1 coverage to clinically managed models and more consumer-centric channels. Commercial availability is expected in Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027. Access will be through three channels: Dario’s MyDario direct-to-consumer shop, health plan marketplaces, and employer B2B2C programs. Dario reports its digital marketplace has served more than 1 million consumers over the last three years, and member interactions will feed blinded data into the DarioIQ AI engine, which is powered by more than 13 billion longitudinal healthcare data points, to support ongoing optimization of outcomes and payer cost savings.
DarioHealth (NASDAQ: DRIO) has priced a registered direct offering of 3,454,559 shares of common stock (or equivalents) at $6.80 per share, structured as an at-the-market transaction under Nasdaq rules. Expected gross proceeds are approximately $23.5 million before placement fees and expenses, with closing targeted on or about July 23, 2026 subject to customary conditions.
A member of the board of directors is participating by purchasing 14,430 shares at $6.93 per share. According to DarioHealth, net proceeds are intended for working capital, investments, acquisitions and general corporate purposes. The securities are being issued off an effective Form S-3 shelf registration (File No. 333-294454), with A.G.P./Alliance Global Partners acting as sole placement agent. The company highlights participation from existing long-term institutional investors alongside a new global fundamental institutional investor.
DarioHealth (NASDAQ: DRIO) announced that a Fortune 50 employer has awarded the company a contract to provide its integrated, AI-powered digital cardiometabolic care platform for employees with diabetes and/or hypertension. The program will cover more than 100,000 eligible employees and is expected to launch in Fall 2026.
According to DarioHealth, annual recurring revenue from this program is expected to begin by year-end 2026 and increase through 2027 and beyond. This is Dario’s fifth Fortune 50 client, and nearly one-quarter of its clients are Fortune 500 companies. The platform targets comorbid chronic conditions using connected devices, human coaching and AI-driven insights via DarioIQ.
DarioHealth (NASDAQ: DRIO) announced that broader deployment of its proprietary AI engine DarioIQ™ is expected to increase annual B2B2C recurring revenue from existing customers by approximately 10%–15%, excluding any impact from future customer wins or condition expansions.
According to DarioHealth, DarioIQ’s AI-driven personalization increased active member engagement by 40% and improved member retention by 20% versus a control group, based on development completed in the first half of 2026. The company reports a program ROI of 2.5x–5x across its solutions.
DarioIQ uses more than 13 billion de-identified proprietary real-world healthcare data points, combining biometric readings from FDA-cleared devices, clinical history and behavioral patterns to optimize outreach. DarioHealth highlights responsible-AI practices and notes that its recent expansion into provider-backed care is expected to connect AI-driven engagement more directly to clinical intervention and reimbursement workflows.
DarioHealth (NASDAQ: DRIO) announced a new agreement with a major Arizona health insurer through its Amwell partnership, making its cardiometabolic digital health solution available to the insurer's ASO employer clients, representing access to hundreds of thousands of covered lives.
The deal supports Dario's channel-led, capital-efficient growth model, expanding recurring revenue opportunities and leveraging a network reaching over 116 million covered lives, with an employer ROI of up to 5x reported in a Sanofi-funded study.
DarioHealth (NASDAQ: DRIO) announced that one of the 5 largest U.S. health insurers extended its agreement and added Dario’s AI-powered hypertension solution after success with its behavioral health program.
The expanded cardiometabolic rollout may roughly triple revenue opportunity from this client, with contributions expected in 2026 and greater impact from 2027. This is the third health plan to expand beyond an initial condition, supporting Dario’s multi-condition strategy. Dario now serves 12 health plans, including 3 national carriers, across 6 chronic condition solutions using Beluga-enabled care delivery.
DarioHealth (NASDAQ: DRIO) appointed former Humana Senior Vice President and Chief Compliance Officer Sean O'Reilly to its Advisory Board.
The move is intended to strengthen compliance, regulatory and payer expertise as Dario advances its AI-enabled digital health platform and channel partner-led growth with health plans, employers and providers.